WO1993019168A1 - Reconstituted cartilage tissue - Google Patents

Reconstituted cartilage tissue Download PDF

Info

Publication number
WO1993019168A1
WO1993019168A1 PCT/CA1993/000111 CA9300111W WO9319168A1 WO 1993019168 A1 WO1993019168 A1 WO 1993019168A1 CA 9300111 W CA9300111 W CA 9300111W WO 9319168 A1 WO9319168 A1 WO 9319168A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
chondrocytes
cartilage tissue
collagen
substrate
Prior art date
Application number
PCT/CA1993/000111
Other languages
French (fr)
Inventor
Rita A. Kandel
Original Assignee
Mount Sinai Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corporation filed Critical Mount Sinai Hospital Corporation
Priority to AU38816/93A priority Critical patent/AU677953B2/en
Priority to JP51613193A priority patent/JP3587305B2/en
Priority to DE69328776T priority patent/DE69328776T2/en
Priority to CA002131904A priority patent/CA2131904C/en
Priority to EP93907686A priority patent/EP0631619B1/en
Priority to AT93907686T priority patent/ATE193550T1/en
Priority to DK93907686T priority patent/DK0631619T3/en
Publication of WO1993019168A1 publication Critical patent/WO1993019168A1/en
Priority to GR20000401884T priority patent/GR3034190T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3612Cartilage, synovial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633Extracellular matrix [ECM]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • A61L27/365Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • A61L27/3654Cartilage, e.g. meniscus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655Chondrocytes; Cartilage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/30756Cartilage endoprostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00365Proteins; Polypeptides; Degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/06Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/50Proteins
    • C12N2533/54Collagen; Gelatin

Definitions

  • the present invention relates to reconstituted cartilage tissue; to a method for producing reconstituted cartilage tissue; and to cartilage tissue reconstituted in vitro from isolated chondrocytes.
  • Cartilage is a specialized tissue found at the end of articulating bones. Cartilage, unlike other connective tissues, lacks blood vessels, nerves, lymphatics and basement membrane. It is responsible for the distribution of load resistance to compressive forces, and the smooth gliding that is part of joint function. Cartilage is composed of chondrocytes which synthesize an abundant extracellular matrix, which is composed of water, collagens, proteoglycans and non- collagenous proteins and lipids. Collagen serves to trap proteoglycans and to provide tensile strength to the tissue. Type II collagen is the predominant collagen in cartilage tissue.
  • the proteoglycans are composed of a variable number of glycosaminoglycan chains, keratan sulphate, chondroitin sulphate and/or dermatan sulphate, and N-linked and O-linked oligosaccharides covalently bound to a protein core.
  • the sulphated glycosaminoglycans are negatively charged resulting in an osmotic swelling pressure that draws in water.
  • articular cartilage appears very homogenous, the matrix organization and composition differ from the superficial to the deep zones (Aydelotte and Kuettner, Conn. Tiss. Res. lfi: 205, 1988; Zanetti et al, J. Cell Biol. lOlt 53, 1985; and Poole et al, J. Anat. 138: 13, 1984).
  • Articular cartilage appears to be composed of zones which show a characteristic gradation of features from the surface of the tissue to the base of the tissue adjacent to the bone. In the superficial zone, for example, chondrocytes are flattened
  • SUBSTITUTESHEET lie parallel to the surface embedded in a matrix that contains tangen ially arranged collagen and few proteoglycans.
  • chondrocytes are spherical and surrounded by a matrix rich in proteoglycans and obliquely organized collagen fibers.
  • the collagen fibers are vertically oriented.
  • the keratan sulphate rich proteoglycans increase in concentration with increasing distance from the cartilage surface (Zanetti et al, supra) .
  • chondrocyte phenotype in these cultures is labile and the chondrocytes dedifferentiate to fibroblasts, as defined by production of type I collagen and small non- aggregating proteoglycans (Von der Mark et al, Nature 267: 531, 1977; and Solursh, Am. J. Med. Gen. 34: 30, 1989).
  • Green (Clin. Orth. Rel. Res. 75:248. 1971) teaches a process for growing chondrocytes in vitro in pelleted aggregate cultures on Millipore cellulose acetate inserts. Green describes the in vitro production of a chondro-myxoid matrix by rabbit chondrocytes. Kuettner et al (J. Cell. Biol. 93:751, (1982)) describe methods of culturing bovine chondrocytes on plastic dishes. Kuettner in U.S. Patent No. 4,356,261 describes methods of culturing chondrocytes in suspension culture in roller bottles. Type II collagen was reported as being the major matrix-associated collagen synthesized in vitro.
  • Kuettner et al analyzed proteoglycans synthesized by the chondrocytes in their culture system by chromatography of 35 S pulse-labelled cultures. The proteoglycans synthesized were compared with those of in vivo bovine articular cartilage.
  • Bassler et al (1986) teach a suspension culture of human chondrocytes wherein aggregates of chondrocytes with secreted matrix were produced by a gyratory shaker. Type II collagen and proteoglycans were detected in the secreted matrix by immunofluoresence and radioimmunoassay. Cheung (In Vitro Cell. Dev. Biol.
  • Type II collagen was detected in the gel matrix cultures by immunofluoresence and acid soluble collagens were examined by SDS polyacrylamJ.de gel electrophoresis.
  • Watt and Dudhia disclose a composite gel of collagen and agarose for the culture of porcine chondrocytes. The composite gel prevented chondrocytes spreading. However, virtually no extracellular matrix was secreted in the low density culture composite gels.
  • Macklis et al (In Vitro Cell. Develop. Biol. 21:180, 1985) teach a collagen surface for culturing peripheral nervous system cells, comprising collagen derivatized to polystyrene plastic culture dishes. Macklis et al disclose that the derivatized coating process yielded enhanced collagen adhesion and increased long term survival of cultured nerve cells, compared to collagen coating produced by absorption techniques.
  • SUMMARY OF THE INVENTION The present inventor has reconstituted cartilage tissue on a substrate in vitro from isolated chondrocytes.
  • the reconstituted cartilage tissue has a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue.
  • the present inventor reconstituted cartilage characterized by a continuous layer of cartilage tissue having a substantial extracellular matrix and possessing zones very similar to those found in bovine cartilage in vivo.
  • the superficial zone is characterized by chondrocytes which are flattened and arranged parallel to the substrate, and. a matrix which contains collagen fibres. Mid and deep zones have spherical chondrocytes and the matrix contains collagen fibres.
  • the reconstituted cartilage tissue ultrastructurally has a pericellular and interterritorial arrangement similar to that of in vivo bovine cartilage.
  • the reconstituted cartilage of the present invention also has a biochemical composition substantially the same as animal articular cartilage.
  • type II collagen is present throughout the reconstituted cartilage and the ratio of galactosamine to glucosamine amino sugars in the glycosaminoglycans in the reconstituted cartilage tissue of the invention is between about 4.5 and 6.5.
  • the reconstituted cartilage tissue of the invention under certain conditions also responds to interleukin 1 ⁇ in a similar manner to in vivo cartilage tissue.
  • the invention relates to cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue.
  • the invention also relates to a method for producing reconstituted cartilage tissue comprising isolating chondrocytes from articular cartilage tissue; forming a monolayer of chondrocytes on a substrate which is selected to permit growth media to be applied above and below the substrate; culturing the chondrocytes on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
  • articular cartilage tissue is removed from the joint of an animal; the cartilage tissue is digested to obtain isolated chondrocytes; a monolayer of chondrocytes is formed on a substrate which is selected to permit growth media to be applied above and below the substrate; the chondrocytes are cultured on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
  • the invention further relates to artificial cartilage tissue reconstituted in vitro by digesting cartilage tissue to obtain isolated chondrocytes; forming a monolayer of chondrocytes on a substrate; culturing the chondrocytes and growth medium to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
  • the invention still further relates to a method of using the reconstituted cartilage tissue of the present invention to test pharmaceutical preparations for efficacy in the treatment of diseases of the joint and to a method of using the reconstituted tissue of the present invention as an implant to replace or repair damaged or deficient cartilage.
  • the invention also relates to a method of treating a bone fracture by inserting the reconstituted tissue of the invention into the site of a bone fracture in a patient and to a method of testing for a substance that affects the growth of cartilage tissue comprising subjecting the tissue to a substance which is suspected of affecting the growth of cartilage tissue and determining the effect of the substance on the tissue.
  • Figure 1 is a ⁇ photomicrograph showing cartilage generated by chondrocytes cultured on collagen-coated inserts (F) and stained with Toluidine blue;
  • Figure 2 is a photomicrograph showing cartilage from the bovine joint;
  • Figure 3 is a photomicrograph of fetal cartilage showing the lack of cellular organization characteristic of articular cartilage (C); .
  • Figure 4 is an electron micrograph of a chondrocyte surrounded by a pericellular matrix (-») and an interterritorial matrix within the cartilage tissue generated in culture on collagen-coated inserts;
  • Figure 5 is an electron micrograph of the interterritorial matrix of reconstituted cartilage tissue showing the presence of collagen fibers with characteristic periodic banding;
  • Figure 6 is a Western blot showing the presence of Type II collagen in a pepsin extract (E) of the cartilage tissue generated in culture and a collagen standard (S) ;
  • Figure 7 is a photomicrograph of a section of reconstituted cartilage tissue incubated with anti-Type II collagen antibody, followed by anti-rabbit IgG conjugated to alkaline phosphate;
  • Figure 8 is a photomicrograph of a section of reconstituted cartilage tissue incubated with antibody directed against Factor VIII related antigen and reacted as in Figure 7.
  • the present invention provides cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue.
  • the reconstituted cartilage tissue of the invention is characterized by a continuous layer of cartilage tissue, having a substantial extracellular matrix, and comprising a superficial zone wherein the chondrocytes are flattened and arranged parallel to the substrate, and mid and deep zones wherein the chondrocytes are spherical and wherein the matrix in the superficial, mid and deep zones contains collagen fibers.
  • the present invention also relates to a method for producing reconstituted cartilage tissue.
  • the method comprises isolating chondrocytes from articular tissue.
  • articular cartilage may be removed from the joint of an animal and it may be digested to obtain isolated chondrocytes.
  • a monolayer of chondrocytes is formed on a substrate and the chondrocytes are cultured in growth media to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
  • the reconstituted cartilage tissue of the present invention may be prepared from chondrocytes isolated from articular cartilage from animals, preferably humans, bovines and rabbits, most preferably humans.
  • a particularly useful system may be prepared from chondrocytes isolated from bovine articular cartilage, for example from the metacarpophalangeal joints.
  • Chondrocytes that may be used in the method of the invention include cells having a chondrocyte phenotype and progenitor cells of chondrocytes such as embryonal cells and mesenchymal cells.
  • the chondrocytes may be isolated using techniques known to those skilled in the art including sequential enzyme digestion techniques, such as those described in Kandel et al, Biochem. Biophys. Acta. 1035:130, 1990.
  • the cartilage may be treated with 0.5% protease followed by 0.04% bacterial collagenase.
  • the chondrocytes are plated on a substrate which is selected to permit growth media to be applied above and below the substrate.
  • the substrate is a porous tissue culture insert, for example a Millicell®-CM insert, which has been coated with an attachment factor. Attachment factors are known in the art, see for example, Streuli and Bissell, J. Cell. Biol. 110:1405, 1990 and Buck and Horwitz, Ann, Rev. Cell Biol. 3:179, 1987.
  • attachment factors include type I collagen, type II collagen, type IV collagen, a synthetic peptide of a segment of collagen, preferably a fifteen amino acid sequence 766 GTPGPQGIAGQRGW 780 which is present in the ⁇ l(l) chain of collagen (Bhatnagar and Qian, 38th Annual Meeting of the Orthopedic Research Society 17: 106, 1992), fibronectin, gelatin, laminin, polylysine, preferably poly-L-lysine and poly-D-lysine, vitronectin, cytotactin, echinonectin, entactin, tenascin, thrombospondin, uvomorulin, biglycan, chondroitin sulfate, decorin, dermatan sulfate, heparin, and hyaluronic acid.
  • the attachment factor used in the method of the invention is collagen, most preferably type I collagen.
  • the chondrocytes are plated at a high cell density of at least 0.1 cm 2 , preferably from 1.0 to 7xl0 6 cm 2 .
  • the substrate is a Millicell®-CM tissue culture insert, pore size 0.4 ⁇ m, coated with a growth attachment factor, preferably collagen, most preferably type I collagen diluted in acetic acid.
  • the insert may subsequently be air dried and sterilized, for example by ultra violet light.
  • the chondrocytes seeded on the coated substrate may be grown in suitable culture conditions.
  • suitable culture media are known in the art, such as Ham's F12 medium.
  • the culture medium may contain serum, for example fetal bovine serum in a concentration range of about 2-15% and may further contain growth factors and ascorbic acid.
  • the culture media is applied above and below the substrate.
  • the cells may be cultured at 37°C in a humidified atmosphere supplemented with C0 2 , for at least 14 days.
  • the cells may be cultured for less than 14 days to obtain a reconstituted product which does not entirely resemble cartilage tissue but which may be suitable for transplantation.
  • the present inventor has found that, after as little as 14 days in culture, the cells will produce a tissue with substantial extracellular matrix, which is substantially identical to in vivo bovine cartilage.
  • the cells produce a substantial extracellular matrix and form a continuous layer of cartilage tissue possessing zones very similar to those found in natural bovine cartilage in vivo.
  • the superficial zone is characterized by chondrocytes having a flattened morphology and a matrix which does not stain, or stains poorly, with toluidine blue, indicating the relative absence of sulphated proteoglycans.
  • Chondrocytes in the mid and deep zones have a spherical appearance and the matrix contains abundant sulphated proteoglycans, as evidenced by staining with toluidine blue.
  • Collagen fibers are present diffusely throughout the matrix.
  • the reconstituted cartilage tissue ultrastructurally has a pericellular and interterritorial arrangement similar to that of in vivo bovine cartilage.
  • the chondrocytes possess abundant rough endoplasmic reticulum and are surrounded by matrix.
  • the pericellular matrix contains numerous thin non-banded collagen fibers.
  • the collagen in the interterritorial matrix is less compacted and embedded in electron translucent amorphous material, similar to articular cartilage.
  • Collagen fibers in the interterritorial region of the matrix exhibit the periodic banding characteristic of collagen fibers in the interterritorial zone of cartilage tissue.
  • the biochemical composition of the reconstituted cartilage tissue is substantially the same as animal articular cartilage tissue.
  • the presence of type II collagen in the reconstituted cartilage tissue is indicative of the differentiated phenotype of chondrocytes.
  • the presence of type II collagen was determined in the reconstituted cartilage tissue by means of polyacrylamide gel electrophoresis and Western blot analysis.
  • Type II collagen is present throughout the reconstituted cartilage tissue as determined by immunohistochemical staining of the cartilage using polyclonal antibody directed against Type II collagen.
  • the ratio of galactosamine to glucosamine amino sugars found in the glycosaminoglycans present in cartilage in the reconstituted cartilage tissue of the present invention is between about 4.5 and 6.5.
  • the reconstituted cartilage tissue under certain conditions responds to interleukin l ⁇ in a similar manner to in vivo cartilage tissue.
  • Interleukin l ⁇ stimulates production of matrix metalloproteases that can degrade cartilage matrix macromolecules and inhibit synthesis of proteoglycans.
  • Treatment of the reconstituted tissue with human recombinant interleukin l ⁇ under certain conditions results in a loss of cartilage and matrix components.
  • the reconstituted cartilage tissue of the present invention can be used as a model system for in vitro studies of cartilage structure, function and development.
  • the reconstituted cartilage tissue of the present invention may be used in the testing of pharmaceutical preparations useful in the treatment of diseases of the joint, for example osteoarthritis, inflammatory arthropathies , septic arthritis and crystalline arthropathies.
  • the reconstituted cartilage tissue of the invention may also be implanted into the joints of patients to replace or repair damaged or deficient cartilage.
  • the cartilage can be used to test angiogenic factors as the cartilage is normally resistant to vascular infiltration.
  • the reconstituted cartilage tissue of the present invention can be used to enhance healing of bone fractures when inserted into the site of a fracture.
  • the reconstituted cartilage tissue of the invention may also be used to identify substances which affect the growth of cartilage tissue i.e. trophic factors.
  • substances which inhibit or stimulate the growth of cartilage tissue may be identified by adding a substance suspected of affecting the growth of cartilage tissue to the reconstituted cartilage tissue of the invention and determining the effect of the substance.
  • Agonists or antagonists of substances which stimulate or inhibit the growth of cartilage tissue may also be identified using the reconstituted tissue of the invention.
  • Chondrocytes were isolated from bovine articular cartilage obtained from metacarpophalangeal joints using the sequential enzyme digestion techniques described in Kandel et al, Biochem. Biophys. Acta. 1053:130 (1990). Briefly, the cartilage was treated with 0.5% protease for one hour and 0.04% bacterial collagenase overnight. The isolated chondrocytes were washed three times and plated at a cell density of approximately 1.5 x 10 6 /cm 2 on collagen-coated Millicell®-CM porous tissue culture inserts.
  • Millicell®-CM inserts were coated with Type I collagen (Vitrogen, Type I collagen. Collagen Corporation), diluted to 1 g/ml with 12 mM acetic acid. Following coating, the inserts were air dried for up to 18 hours and sterilized with ultraviolet light for 15 minutes.
  • the collagen-coated inserts, seeded with chondrocytes were placed in sterile tissue culture wells and cultured in Ham's F12 medium, supplemented with 5% fetal bovine serum. The cells were cultured at 37°C in a humidified atmosphere supplemented with 5% C0 2 . The medium was changed 2.5 to 3 days after the initial plating and every 2 days thereafter.
  • the volume of medium added depended on the size of inserts used. For the larger inserts (30 mm) 1.5 ml of medium was placed on top of the insert and 1.0 ml was placed underneath. The inserts were harvested at selected time intervals up until 3 months, fixed and examined by light or electron microscopy.
  • the inserts were fixed in 10% formalin, embedded in paraffin and cut into sections approximately 5 ⁇ m thick. The sections were stained with either hematoxylin and eosin to visualize the cells or with the cationic dye, toluidine blue, to stain sulphated proteoglycans.
  • the insert culture were fixed in 2% glutaraldehyde for one hour at room temperature. The inserts were washed with phosphate buffer and then immersed in 1% osmium tetraoxide for one hour at room temperature.
  • the inserts were washed with a phosphate buffer and dehydrated in graded ethanols to 100% ethanol.
  • the inserts were immersed in 100% propylene oxide for 20 minutes, then embedded in plastic resin (Spurr®) and polymerized overnight at 70°C. Thin sections were cut and stained with uranyl acetate and lead citrate before examination by electron microscopy.
  • FIG. 1 shows the organization of chondrocytes in cartilage tissue dissected from the bovine joint. The chondrocytes in the superficial regions are flattened and the chondrocytes in the deep layers are more spherical. Toluidine blue staining shows the presence of sulphated proteoglycans throughout the cartilage. The staining is lighter in the superficial zone suggesting there are fewer proteoglycans present.
  • Fetal cartilage has no specific cellular organization as is shown in Figure 3.
  • the cartilage tissue grown in vitro, and shown in Figure 1, was found to closely resemble in vivo bovine articular cartilage. Examination of 4 week old cultures by light microscopy showed that the cells had produced abundant extracellular matrix and formed a continuous layer of cartilage tissue possessing zones very similar to those found in natural bovine cartilage in vivo.
  • the superficial zone was characterized by chondrocytes having a flattened morphology and a matrix which did not stain with toluidine blue, indicating the relative absence of sulphated proteoglycans.
  • Chondrocytes in the mid zone had a less flattened appearance and the matrix contained sulphated proteoglycans, as evidenced by the metachromasia produced by toluidine blue staining. Chondrocytes in the deep zone were spherical in appearance and the matrix was metachromatic. Examination by polarized light microscopy showed the birefringence, indicative of collagen fibers.
  • Example 2 In Vitro Synthesis of Type II Collagen The presence of type II collagen in the cartilage tissue grown in vitro was measured to confirm that the cultured chondrocytes had maintained their differentiated phenotype.
  • Chondrocyte cultures were established, following the procedures outlined in Example 1 above, and maintained in culture for 2-4 weeks.
  • the cartilage tissue was extracted with 100 ⁇ g/ml of pepsin at 4°C. After 24 hours an additional lOO ⁇ g of pepsin was added and the extraction continued for another 24 hours.
  • the pepsin extract was neutralized with the addition of an equal volume of Laemmli's buffer.
  • the presence of type II collagen was determined by polyacrylamide gel electrophoresis in the presence of sodium dodecylsulfate (SDS-PAGE) according to the procedure of Laemmli (U.K., Nature (London) 227, 680 (1974)). An 8% polyacrylamide gel was used.
  • the band was transferred electrophoretically from the gel to nitrocellulose sheets and incubated with one of two antibodies directed against type II collagen or an antibody directed against type I collagen (Southern Biotechnology Assoc, U.S.A.
  • One anti-type II collagen monoclonal antibody was obtained from Developmental Studies Hybridoma Bank, Iowa and one was a polyclonal antibody obtained from Southern Biotechnology Assoc. U.S.A.
  • the blots were subjected to three washes and incubated for one hour in alkaline phosphatase conjugated to anti-IgG antibody. Blots were washed 3 times and developed with NBT/BCIP (Pro ega, U.S.A.) from 1 to 30 minutes, until colour developed.
  • Type II collagen was detected in the cultures as shown in Figure 6. Only type II collagen was detected in the pepsin extract of the reconstituted cartilage tissue, as indicated by the arrow on Figure 6. The results confirm that type II collagen is the major collagen produced by the chondrocyte culture.
  • the distribution of type II collagen in the chondrocyte cultures was examined as follows. Frozen sections of the cultured collagen tissue were predigested with 300 I.U. testicular hyaluronidase at 37°C for 15 minutes. The sections were washed in phosphate buffered saline and incubated with polyclonal anti-type II collagen antibody (Southern Biotechnology Associates . 1:100 dilution), for 3 hours at room temperature. The sections were washed in phosphate buffered saline and then incubated for 45 minutes with anti-rabbit IgG antibody conjugated to alkaline phosphate (Vector, U.S.A.). The sections were washed three times.
  • Ratio of Galactosamine to Glucosamine The ratio of galactosamine, which is present in chondroitin sulphate and dermatan sulphate, to glucosamine, which is present in hyaluronate and keratan sulphate, was determined in the insert cultures and compared to the ratios in bovine articular cartilage.
  • the tissue sample comprising bovine articular cartilage or cultured cartilage tissue following papain digestion was hydrolysed with 6 N hydrochloric acid and examined by high pressure liquid chromatography using a Water's Pico Tag amino acid analysis system (Biotechnology Centre, University of Toronto) the ratio of galactosamine to glucosamine in the bovine articular cartilage was 5.55, whereas in the cultured cartilage, the ratio was 5.14. There was no significant difference between the ratios, indicating that the ratio of these glycosaminoglycans are likely similar in both the intact tissue and the artificial tissue generated in culture.
  • the ratio of galactosamine to glucosamine is indicative of the types of glycosaminoglycans present in the extracellular matrix of the bovine cartilage and the cultured cartilage tissue.

Abstract

The present invention relates to cartilage tissue reconstituted on a substrate; to a method for producing reconstituted cartilage tissue; and to cartilage tissue reconstituted in vitro from isolated chondrocytes cultured on a substrate.

Description

- 1 -
Title: RECONSTITUTED CARTILAGE TISSUE
FIELD OF THE INVENTION
The present invention relates to reconstituted cartilage tissue; to a method for producing reconstituted cartilage tissue; and to cartilage tissue reconstituted in vitro from isolated chondrocytes.
BACKGROUND OF THE INVENTION
Articular cartilage is a specialized tissue found at the end of articulating bones. Cartilage, unlike other connective tissues, lacks blood vessels, nerves, lymphatics and basement membrane. It is responsible for the distribution of load resistance to compressive forces, and the smooth gliding that is part of joint function. Cartilage is composed of chondrocytes which synthesize an abundant extracellular matrix, which is composed of water, collagens, proteoglycans and non- collagenous proteins and lipids. Collagen serves to trap proteoglycans and to provide tensile strength to the tissue. Type II collagen is the predominant collagen in cartilage tissue. The proteoglycans are composed of a variable number of glycosaminoglycan chains, keratan sulphate, chondroitin sulphate and/or dermatan sulphate, and N-linked and O-linked oligosaccharides covalently bound to a protein core. The sulphated glycosaminoglycans are negatively charged resulting in an osmotic swelling pressure that draws in water.
Although, histologically, articular cartilage appears very homogenous, the matrix organization and composition differ from the superficial to the deep zones (Aydelotte and Kuettner, Conn. Tiss. Res. lfi: 205, 1988; Zanetti et al, J. Cell Biol. lOlt 53, 1985; and Poole et al, J. Anat. 138: 13, 1984). Articular cartilage appears to be composed of zones which show a characteristic gradation of features from the surface of the tissue to the base of the tissue adjacent to the bone. In the superficial zone, for example, chondrocytes are flattened
SUBSTITUTESHEET and lie parallel to the surface embedded in a matrix that contains tangen ially arranged collagen and few proteoglycans. In the mid zone, chondrocytes are spherical and surrounded by a matrix rich in proteoglycans and obliquely organized collagen fibers. In the deep zone, close to the bone, the collagen fibers are vertically oriented. The keratan sulphate rich proteoglycans increase in concentration with increasing distance from the cartilage surface (Zanetti et al, supra) .
Ultrastructural variation is evident between the pericellular and interterritorial matrix areas. The pericellular collagen fibers are much thinner and do not exhibit the usual 68 ^nm periodicity characteristic of collagen in the interterritorial zone. It is not known how these zones are established or maintained (Poole et al, supra; Urban and Bayliss, Biochem. Biophys. Acta. 992; 59, 1989; Brown et al,-Conn. Tiss. Res. 24: 157, 1990; Schneiderman et al J. Orthop. Res. 4.: 393, 1986). Studies of cartilage organization and pathophysiology have been severely restricted by the limited availability of cartilage tissue and the inability of in vitro culture systems to mimic the organization of in vivo cartilage tissue. In vivo cartilage has been removed and maintained in explant cultures, but there are several problems associated with these cultures (Poole et al supra: Lane and Brighton, Arth. Rheum 2: 235, 197.4; and Morales et al, J. Biol. Chem. 259: 6720, 1984). There is a loss of matrix molecules from the cartilage during culture, and the amount of cartilage available for experimentation is therefore limited. Chondrocytes have been isolated from cartilage and grown in monolayer culture systems (Manning and Bonner, Arth. Rheum. JD: 235, 1967; Horwitz and Dorfman, J. Cell Biol. 45.: 434, 1970; and Green, Clin. Orthop. Rel. Res. 7_5: 248, 1971). However, chondrocyte phenotype in these cultures is labile and the chondrocytes dedifferentiate to fibroblasts, as defined by production of type I collagen and small non- aggregating proteoglycans (Von der Mark et al, Nature 267: 531, 1977; and Solursh, Am. J. Med. Gen. 34: 30, 1989).
Maintaining chondrocytes in a spherical shape has been shown to slow down or prevent dedifferentiation of the chondrocyte phenotype (Watt and Dudhia, Differentiation 3£: 140, 1988). Accordingly, culture systems have been developed to maintain the cells in a spherical shape. Primary cell cultures either plated at high density in monolayer or droplet form, in suspension culture, in collagen gel, in or on agarose gel, in composition agarose-collagen gels, in alginate or on apatite beads, or a combination of monolayer culture followed by transfer to agarose culture have been employed in an attempt to slow down or prevent dedifferentiation (Kuettner et al, J. Cell. Biol. 13: 743, 1982; Van Kampen and Veldhuijzen, Exp. Cell. Res. 140: 440, 1982; Delbruck et al, Conn. Tiss. Res. J5: 155, 1986; Thompson et al, Exp. Cell. Res. 157: 483, 1985; Bassler et al, In Vitro 22: 113, 1986; Cheung, In Vitro Cell. Dev. Biol. .21: 353, 1985; Guo et al. Conn. Tiss. Res. .19: 277, 1989; Aulthouse et al. In Vitro 25: 659, 1989; and Solursh, J. Cell. Biochem. 45.: 258, 1991).
Alternative approaches to maintaining the chondrocyte phenotype have been to induce chondrogenesis by growing mesenchymal cells in diffusion chambers or in monolayer in the presence of beta TGF (O'Driscoll et al. Trans. Orthop. Res. 37: 125, 1991 and Nakahara et al. Bone 11: 181, 1990), or perichondrial grafts (Amiel et al, Conn. Tiss. Res. 18: 27, 1988). Under all of the above conditions the chondrocytes maintain at least a partial chondrocyte phenotype, as indicated by the synthesis of type II collagen and proteoglycans specific to articular cartilage. However, there are a number of problems with these types of cultures. Proliferation in some of the cultures is inhibited so that only a limited number of cells can be generated. It has also proved difficult to isolate cells from these. cultures. The most important limitation, however, is that none of these culture systems can mimic the in vivo morphology of articular cartilage, including the cellular and matrix organization described above.
Green (Clin. Orth. Rel. Res. 75:248. 1971) teaches a process for growing chondrocytes in vitro in pelleted aggregate cultures on Millipore cellulose acetate inserts. Green describes the in vitro production of a chondro-myxoid matrix by rabbit chondrocytes. Kuettner et al (J. Cell. Biol. 93:751, (1982)) describe methods of culturing bovine chondrocytes on plastic dishes. Kuettner in U.S. Patent No. 4,356,261 describes methods of culturing chondrocytes in suspension culture in roller bottles. Type II collagen was reported as being the major matrix-associated collagen synthesized in vitro. Kuettner et al analyzed proteoglycans synthesized by the chondrocytes in their culture system by chromatography of 35S pulse-labelled cultures. The proteoglycans synthesized were compared with those of in vivo bovine articular cartilage. Bassler et al (1986) teach a suspension culture of human chondrocytes wherein aggregates of chondrocytes with secreted matrix were produced by a gyratory shaker. Type II collagen and proteoglycans were detected in the secreted matrix by immunofluoresence and radioimmunoassay. Cheung (In Vitro Cell. Dev. Biol. 21:353, 1985) teaches a method of culturing canine chondrocytes on porous hydroxyapatite ceramic granules. The cells reportedly proliferated and secreted metachromatic extracellular matrix for up to 13 months. An agarose gel matrix has also been described as suitable for the in vitro culture of human chondrocytes (Delbruck et al. Conn. Tiss. Res. 15:155, 1986). Delbruck et al disclosed human chondrocytes distributed in the agarose and forming a pericellular region surrounded by an interterritorial-like region. Type II collagen was detected in the gel matrix cultures by immunofluoresence and acid soluble collagens were examined by SDS polyacrylamJ.de gel electrophoresis. Watt and Dudhia (Differentiation 38:140, 1988) disclose a composite gel of collagen and agarose for the culture of porcine chondrocytes. The composite gel prevented chondrocytes spreading. However, virtually no extracellular matrix was secreted in the low density culture composite gels.
Macklis et al (In Vitro Cell. Develop. Biol. 21:180, 1985) teach a collagen surface for culturing peripheral nervous system cells, comprising collagen derivatized to polystyrene plastic culture dishes. Macklis et al disclose that the derivatized coating process yielded enhanced collagen adhesion and increased long term survival of cultured nerve cells, compared to collagen coating produced by absorption techniques. SUMMARY OF THE INVENTION The present inventor has reconstituted cartilage tissue on a substrate in vitro from isolated chondrocytes. The reconstituted cartilage tissue has a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue. In particular, the present inventor reconstituted cartilage characterized by a continuous layer of cartilage tissue having a substantial extracellular matrix and possessing zones very similar to those found in bovine cartilage in vivo. The superficial zone is characterized by chondrocytes which are flattened and arranged parallel to the substrate, and. a matrix which contains collagen fibres. Mid and deep zones have spherical chondrocytes and the matrix contains collagen fibres. The reconstituted cartilage tissue ultrastructurally has a pericellular and interterritorial arrangement similar to that of in vivo bovine cartilage.
The reconstituted cartilage of the present invention also has a biochemical composition substantially the same as animal articular cartilage. In particular, type II collagen is present throughout the reconstituted cartilage and the ratio of galactosamine to glucosamine amino sugars in the glycosaminoglycans in the reconstituted cartilage tissue of the invention is between about 4.5 and 6.5. The reconstituted cartilage tissue of the invention under certain conditions also responds to interleukin 1 β in a similar manner to in vivo cartilage tissue. Broadly stated the invention relates to cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue. The invention also relates to a method for producing reconstituted cartilage tissue comprising isolating chondrocytes from articular cartilage tissue; forming a monolayer of chondrocytes on a substrate which is selected to permit growth media to be applied above and below the substrate; culturing the chondrocytes on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
In one embodiment of the method of the invention, articular cartilage tissue is removed from the joint of an animal; the cartilage tissue is digested to obtain isolated chondrocytes; a monolayer of chondrocytes is formed on a substrate which is selected to permit growth media to be applied above and below the substrate; the chondrocytes are cultured on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
The invention further relates to artificial cartilage tissue reconstituted in vitro by digesting cartilage tissue to obtain isolated chondrocytes; forming a monolayer of chondrocytes on a substrate; culturing the chondrocytes and growth medium to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
The invention still further relates to a method of using the reconstituted cartilage tissue of the present invention to test pharmaceutical preparations for efficacy in the treatment of diseases of the joint and to a method of using the reconstituted tissue of the present invention as an implant to replace or repair damaged or deficient cartilage. The invention also relates to a method of treating a bone fracture by inserting the reconstituted tissue of the invention into the site of a bone fracture in a patient and to a method of testing for a substance that affects the growth of cartilage tissue comprising subjecting the tissue to a substance which is suspected of affecting the growth of cartilage tissue and determining the effect of the substance on the tissue. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a^photomicrograph showing cartilage generated by chondrocytes cultured on collagen-coated inserts (F) and stained with Toluidine blue; Figure 2 is a photomicrograph showing cartilage from the bovine joint;
Figure 3 is a photomicrograph of fetal cartilage showing the lack of cellular organization characteristic of articular cartilage (C); . Figure 4 is an electron micrograph of a chondrocyte surrounded by a pericellular matrix (-») and an interterritorial matrix within the cartilage tissue generated in culture on collagen-coated inserts;
Figure 5 is an electron micrograph of the interterritorial matrix of reconstituted cartilage tissue showing the presence of collagen fibers with characteristic periodic banding;
Figure 6 is a Western blot showing the presence of Type II collagen in a pepsin extract (E) of the cartilage tissue generated in culture and a collagen standard (S) ;
Figure 7 is a photomicrograph of a section of reconstituted cartilage tissue incubated with anti-Type II collagen antibody, followed by anti-rabbit IgG conjugated to alkaline phosphate;
Figure 8 is a photomicrograph of a section of reconstituted cartilage tissue incubated with antibody directed against Factor VIII related antigen and reacted as in Figure 7. DETAILED DESCRIPTION OF THE INVENTION
As hereinbefore mentioned, the present invention provides cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue.
The reconstituted cartilage tissue of the invention is characterized by a continuous layer of cartilage tissue, having a substantial extracellular matrix, and comprising a superficial zone wherein the chondrocytes are flattened and arranged parallel to the substrate, and mid and deep zones wherein the chondrocytes are spherical and wherein the matrix in the superficial, mid and deep zones contains collagen fibers.
The present invention also relates to a method for producing reconstituted cartilage tissue. The method comprises isolating chondrocytes from articular tissue. In particular, articular cartilage may be removed from the joint of an animal and it may be digested to obtain isolated chondrocytes. A monolayer of chondrocytes is formed on a substrate and the chondrocytes are cultured in growth media to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
The reconstituted cartilage tissue of the present invention may be prepared from chondrocytes isolated from articular cartilage from animals, preferably humans, bovines and rabbits, most preferably humans. A particularly useful system may be prepared from chondrocytes isolated from bovine articular cartilage, for example from the metacarpophalangeal joints. Chondrocytes that may be used in the method of the invention include cells having a chondrocyte phenotype and progenitor cells of chondrocytes such as embryonal cells and mesenchymal cells.
The chondrocytes may be isolated using techniques known to those skilled in the art including sequential enzyme digestion techniques, such as those described in Kandel et al, Biochem. Biophys. Acta. 1035:130, 1990. For example, the cartilage may be treated with 0.5% protease followed by 0.04% bacterial collagenase.
The chondrocytes are plated on a substrate which is selected to permit growth media to be applied above and below the substrate. Preferably the substrate is a porous tissue culture insert, for example a Millicell®-CM insert, which has been coated with an attachment factor. Attachment factors are known in the art, see for example, Streuli and Bissell, J. Cell. Biol. 110:1405, 1990 and Buck and Horwitz, Ann, Rev. Cell Biol. 3:179, 1987. Examples of attachment factors include type I collagen, type II collagen, type IV collagen, a synthetic peptide of a segment of collagen, preferably a fifteen amino acid sequence 766GTPGPQGIAGQRGW780 which is present in the αl(l) chain of collagen (Bhatnagar and Qian, 38th Annual Meeting of the Orthopedic Research Society 17: 106, 1992), fibronectin, gelatin, laminin, polylysine, preferably poly-L-lysine and poly-D-lysine, vitronectin, cytotactin, echinonectin, entactin, tenascin, thrombospondin, uvomorulin, biglycan, chondroitin sulfate, decorin, dermatan sulfate, heparin, and hyaluronic acid. Preferably, the attachment factor used in the method of the invention is collagen, most preferably type I collagen. The chondrocytes are plated at a high cell density of at least 0.1 cm2, preferably from 1.0 to 7xl06 cm2. In a preferred embodiment of the invention the substrate is a Millicell®-CM tissue culture insert, pore size 0.4μm, coated with a growth attachment factor, preferably collagen, most preferably type I collagen diluted in acetic acid. The insert may subsequently be air dried and sterilized, for example by ultra violet light.
The chondrocytes seeded on the coated substrate, may be grown in suitable culture conditions. Examples of suitable culture media are known in the art, such as Ham's F12 medium. The culture medium may contain serum, for example fetal bovine serum in a concentration range of about 2-15% and may further contain growth factors and ascorbic acid. The culture media is applied above and below the substrate. The cells may be cultured at 37°C in a humidified atmosphere supplemented with C02, for at least 14 days. The cells may be cultured for less than 14 days to obtain a reconstituted product which does not entirely resemble cartilage tissue but which may be suitable for transplantation.
The present inventor has found that, after as little as 14 days in culture, the cells will produce a tissue with substantial extracellular matrix, which is substantially identical to in vivo bovine cartilage. The cells produce a substantial extracellular matrix and form a continuous layer of cartilage tissue possessing zones very similar to those found in natural bovine cartilage in vivo. The superficial zone is characterized by chondrocytes having a flattened morphology and a matrix which does not stain, or stains poorly, with toluidine blue, indicating the relative absence of sulphated proteoglycans. Chondrocytes in the mid and deep zones have a spherical appearance and the matrix contains abundant sulphated proteoglycans, as evidenced by staining with toluidine blue. Collagen fibers are present diffusely throughout the matrix.
The reconstituted cartilage tissue ultrastructurally has a pericellular and interterritorial arrangement similar to that of in vivo bovine cartilage. The chondrocytes possess abundant rough endoplasmic reticulum and are surrounded by matrix. The pericellular matrix contains numerous thin non-banded collagen fibers. The collagen in the interterritorial matrix is less compacted and embedded in electron translucent amorphous material, similar to articular cartilage. Collagen fibers in the interterritorial region of the matrix exhibit the periodic banding characteristic of collagen fibers in the interterritorial zone of cartilage tissue.
The biochemical composition of the reconstituted cartilage tissue is substantially the same as animal articular cartilage tissue. For example, the presence of type II collagen in the reconstituted cartilage tissue is indicative of the differentiated phenotype of chondrocytes. The presence of type II collagen was determined in the reconstituted cartilage tissue by means of polyacrylamide gel electrophoresis and Western blot analysis. Type II collagen is present throughout the reconstituted cartilage tissue as determined by immunohistochemical staining of the cartilage using polyclonal antibody directed against Type II collagen. The ratio of galactosamine to glucosamine amino sugars found in the glycosaminoglycans present in cartilage in the reconstituted cartilage tissue of the present invention is between about 4.5 and 6.5.
The reconstituted cartilage tissue under certain conditions responds to interleukin lβ in a similar manner to in vivo cartilage tissue. Interleukin lβ stimulates production of matrix metalloproteases that can degrade cartilage matrix macromolecules and inhibit synthesis of proteoglycans. Treatment of the reconstituted tissue with human recombinant interleukin lβ under certain conditions results in a loss of cartilage and matrix components.
The reconstituted cartilage tissue of the present invention can be used as a model system for in vitro studies of cartilage structure, function and development. In particular, the reconstituted cartilage tissue of the present invention may be used in the testing of pharmaceutical preparations useful in the treatment of diseases of the joint, for example osteoarthritis, inflammatory arthropathies , septic arthritis and crystalline arthropathies. The reconstituted cartilage tissue of the invention may also be implanted into the joints of patients to replace or repair damaged or deficient cartilage. In addition the cartilage can be used to test angiogenic factors as the cartilage is normally resistant to vascular infiltration. It is also contemplated that the reconstituted cartilage tissue of the present invention can be used to enhance healing of bone fractures when inserted into the site of a fracture. The reconstituted cartilage tissue of the invention may also be used to identify substances which affect the growth of cartilage tissue i.e. trophic factors. Thus, substances which inhibit or stimulate the growth of cartilage tissue may be identified by adding a substance suspected of affecting the growth of cartilage tissue to the reconstituted cartilage tissue of the invention and determining the effect of the substance. Agonists or antagonists of substances which stimulate or inhibit the growth of cartilage tissue may also be identified using the reconstituted tissue of the invention.
The following non-limiting examples are illustrative of the present invention:
Example 1 Reconstituting Cartilage Tissue in Vitro
Chondrocytes were isolated from bovine articular cartilage obtained from metacarpophalangeal joints using the sequential enzyme digestion techniques described in Kandel et al, Biochem. Biophys. Acta. 1053:130 (1990). Briefly, the cartilage was treated with 0.5% protease for one hour and 0.04% bacterial collagenase overnight. The isolated chondrocytes were washed three times and plated at a cell density of approximately 1.5 x 106/cm2 on collagen-coated Millicell®-CM porous tissue culture inserts.
To prepare the collagen-coated inserts, Millicell®-CM inserts, pore size 0.4 μm, were coated with Type I collagen (Vitrogen, Type I collagen. Collagen Corporation), diluted to 1 g/ml with 12 mM acetic acid. Following coating, the inserts were air dried for up to 18 hours and sterilized with ultraviolet light for 15 minutes. The collagen-coated inserts, seeded with chondrocytes, were placed in sterile tissue culture wells and cultured in Ham's F12 medium, supplemented with 5% fetal bovine serum. The cells were cultured at 37°C in a humidified atmosphere supplemented with 5% C02. The medium was changed 2.5 to 3 days after the initial plating and every 2 days thereafter. The volume of medium added depended on the size of inserts used. For the larger inserts (30 mm) 1.5 ml of medium was placed on top of the insert and 1.0 ml was placed underneath. The inserts were harvested at selected time intervals up until 3 months, fixed and examined by light or electron microscopy.
For light microscopy, the inserts were fixed in 10% formalin, embedded in paraffin and cut into sections approximately 5 μm thick. The sections were stained with either hematoxylin and eosin to visualize the cells or with the cationic dye, toluidine blue, to stain sulphated proteoglycans. In vivo samples of intact cartilage from bovine metacarpophalangeal joints were similarly processed for light microscopy. For electron microscopy, representative portions of the insert culture were fixed in 2% glutaraldehyde for one hour at room temperature. The inserts were washed with phosphate buffer and then immersed in 1% osmium tetraoxide for one hour at room temperature. The inserts were washed with a phosphate buffer and dehydrated in graded ethanols to 100% ethanol. The inserts were immersed in 100% propylene oxide for 20 minutes, then embedded in plastic resin (Spurr®) and polymerized overnight at 70°C. Thin sections were cut and stained with uranyl acetate and lead citrate before examination by electron microscopy.
After 2 weeks in culture the cells had produced a tissue with abundant extracellular matrix which was substantially identical to bovine cartilage in vivo. Morphological comparisons were made between the cartilage tissue produced by in vitro culture, shown in Figure 1 and the in vivo cartilage tissue from the bovine joint, known in the art, shown in Figure 2. Figure 2 shows the organization of chondrocytes in cartilage tissue dissected from the bovine joint. The chondrocytes in the superficial regions are flattened and the chondrocytes in the deep layers are more spherical. Toluidine blue staining shows the presence of sulphated proteoglycans throughout the cartilage. The staining is lighter in the superficial zone suggesting there are fewer proteoglycans present. Fetal cartilage has no specific cellular organization as is shown in Figure 3. The cartilage tissue grown in vitro, and shown in Figure 1, was found to closely resemble in vivo bovine articular cartilage. Examination of 4 week old cultures by light microscopy showed that the cells had produced abundant extracellular matrix and formed a continuous layer of cartilage tissue possessing zones very similar to those found in natural bovine cartilage in vivo. The superficial zone was characterized by chondrocytes having a flattened morphology and a matrix which did not stain with toluidine blue, indicating the relative absence of sulphated proteoglycans. Chondrocytes in the mid zone had a less flattened appearance and the matrix contained sulphated proteoglycans, as evidenced by the metachromasia produced by toluidine blue staining. Chondrocytes in the deep zone were spherical in appearance and the matrix was metachromatic. Examination by polarized light microscopy showed the birefringence, indicative of collagen fibers.
Examination by electron microscopy showed that the cultured tissue had a pericellular and interterritorial arrangement similar to that of bovine cartilage, as shown in Figure 4. Chondrocytes with abundant rough endoplasmic reticulum were observed surrounded by matrix. The pericellular matrix contained numerous thin nonbanded collagen fibers. The collagen in the interterritorial matrix was less compacted and embedded in an electron translucent amorphous material similar to articular cartilage. Figure 5 shows collagen fibers from the interterritorial matrix of reconstituted cartilage tissue. The collagen fibers exhibit the periodic banding characteristic of collagen fibers in the interterritorial zone of in vivo cartilage tissue. Numerous electron dense granules were present, which appeared as dots throughout the matrix, indicating the presence of proteoglycans.
Example 2 In Vitro Synthesis of Type II Collagen The presence of type II collagen in the cartilage tissue grown in vitro was measured to confirm that the cultured chondrocytes had maintained their differentiated phenotype.
Chondrocyte cultures were established, following the procedures outlined in Example 1 above, and maintained in culture for 2-4 weeks. The cartilage tissue was extracted with 100 μg/ml of pepsin at 4°C. After 24 hours an additional lOOμg of pepsin was added and the extraction continued for another 24 hours. The pepsin extract was neutralized with the addition of an equal volume of Laemmli's buffer. The presence of type II collagen was determined by polyacrylamide gel electrophoresis in the presence of sodium dodecylsulfate (SDS-PAGE) according to the procedure of Laemmli (U.K., Nature (London) 227, 680 (1974)). An 8% polyacrylamide gel was used. A sample of pepsin extract was applied to the gel and electrophoresed at 100 Ma for about 2 hours. Bands on the gel were visualized by staining with Coomassie Brilliant Blue. Only one band was observed co-migrating with the collagen standard. The identity of the band was confirmed by Western blot analysis to be type II collagen. TheWestern blot analysis was carried out by known standard techniques, generally as described in Coding, J.W. , Monoclonal Antibodies: Principles and Practice, 2nd ed.. Academic Press, London pp. 195-199, 1986. The band was transferred electrophoretically from the gel to nitrocellulose sheets and incubated with one of two antibodies directed against type II collagen or an antibody directed against type I collagen (Southern Biotechnology Assoc, U.S.A. One anti-type II collagen monoclonal antibody was obtained from Developmental Studies Hybridoma Bank, Iowa and one was a polyclonal antibody obtained from Southern Biotechnology Assoc. U.S.A. The blots were subjected to three washes and incubated for one hour in alkaline phosphatase conjugated to anti-IgG antibody. Blots were washed 3 times and developed with NBT/BCIP (Pro ega, U.S.A.) from 1 to 30 minutes, until colour developed. Type II collagen was detected in the cultures as shown in Figure 6. Only type II collagen was detected in the pepsin extract of the reconstituted cartilage tissue, as indicated by the arrow on Figure 6. The results confirm that type II collagen is the major collagen produced by the chondrocyte culture.
The distribution of type II collagen in the chondrocyte cultures was examined as follows. Frozen sections of the cultured collagen tissue were predigested with 300 I.U. testicular hyaluronidase at 37°C for 15 minutes. The sections were washed in phosphate buffered saline and incubated with polyclonal anti-type II collagen antibody (Southern Biotechnology Associates . 1:100 dilution), for 3 hours at room temperature. The sections were washed in phosphate buffered saline and then incubated for 45 minutes with anti-rabbit IgG antibody conjugated to alkaline phosphate (Vector, U.S.A.). The sections were washed three times. 5-Bromo-4-chloro-3- indolyl phosphate nitroblue tetrazolium was added for substrate, and colour development. The sections were then counterstained with nuclear fast red stain, coverslipped and examined by light microscopy. The blue staining indicates the presence of Type II collagen throughout the cartilage, as shown in Figure 7. Control sections were stained with antibody directed against Factor VIII related antigen, which is not present in cartilage. The cartilage matrix was unstained in the control sections, as shown in Figure 8. Example 3
Interleukin 1 Stimulates Matrix Loss in the Chondrocyte Culture. Chondrocyte cultures were established as described above and grown for 2 weeks. The cultures were incubated with 10 ng/ml of human recombinant interleukin lβ (Ciba-Geigy, Switzerland) for seven days. After seven days the cultures were processed for light microscopy as described above in Example 1 and assessed histologically following staining with toluidine blue. Toluidine blue staining was taken as an indication of the presence of sulphated proteoglycans. Toluidine blue staining was greatly diminished in cultures treated with IL-1, compared to untreated controls, indicating a loss of cartilage and matrix components in the remaining cartilage. Example 4
Ratio of Galactosamine to Glucosamine The ratio of galactosamine, which is present in chondroitin sulphate and dermatan sulphate, to glucosamine, which is present in hyaluronate and keratan sulphate, was determined in the insert cultures and compared to the ratios in bovine articular cartilage.
The tissue sample, comprising bovine articular cartilage or cultured cartilage tissue following papain digestion was hydrolysed with 6 N hydrochloric acid and examined by high pressure liquid chromatography using a Water's Pico Tag amino acid analysis system (Biotechnology Centre, University of Toronto) the ratio of galactosamine to glucosamine in the bovine articular cartilage was 5.55, whereas in the cultured cartilage, the ratio was 5.14. There was no significant difference between the ratios, indicating that the ratio of these glycosaminoglycans are likely similar in both the intact tissue and the artificial tissue generated in culture. The ratio of galactosamine to glucosamine is indicative of the types of glycosaminoglycans present in the extracellular matrix of the bovine cartilage and the cultured cartilage tissue.

Claims

I CLAIM:
1. Cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue.
2. Cartilage tissue as claimed in claim 1 which is further characterized by the presence of proteoglycans.
3. Cartilage tissue reconstituted in vitro having a biochemical composition and cellular and matrix organization substantially the same as animal articular cartilage tissue and characterized by a continuous layer of cartilage tissue, having a substantial extracellular matrix and comprising: a superficial zone wherein chondrocytes are flattened and arranged parallel to the substrate; mid and deep zones wherein the chondrocytes are spherical; and wherein the matrix in the superficial, mid and deep zones contains collagen fibres.
4. Cartilage tissue as claimed in claim 3 which is further characterized as follows: type II collagen is present; galactosamine and glucosamine are present in a ratio of between 4.5 and 6.5; and there is an increasing abundance of sulphated proteoglycans from the superficial to the mid and deep zones.
5. Cartilage tissue as claimed in claim 1 in combination with a substrate.
6. Cartilage tissue as claimed in claim 5 wherein the substrate comprises a porous tissue culture insert coated with at least one attachment factor.
7. Cartilage tissue as claimed in claim 6 wherein the porous tissue culture insert is a Millicell®-CM.
8. Cartilage tissue as claimed in claim 6 wherein at least one of the attachment factors is collagen.
9. Cartilage tissue as claimed in claim 8 wherein the collagen is type I collagen.
10. A method for producing reconstituted cartilage tissue comprising: isolating chondrocytes from articular cartilage tissue; forming a monolayer of chondrocytes on a substrate which is selected to permit growth media to be applied above and below the substrate; culturing the chondrocytes on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
11. A method for producing reconstituted cartilage tissue comprising: removing articular cartilage tissue from an animal; digesting said articular cartilage tissue o obtain isolated chondrocytes; forming a monolayer of chondrocytes on a substrate which is selected to permit growth media to be applied above and below the substrate; culturing the chondrocytes on the substrate in growth media which is applied above and below the chondrocytes on the substrate, to produce a tissue having a biochemical composition and cellular and matrix organization substantially the same as articular cartilage tissue.
12. A method as claimed in claim 10 wherein the substrate is a porous tissue culture insert coated with at least one attachment factor.
13. A method as claimed in claim 11 wherein the substrate is a porous tissue culture insert coated with at least one attachment factor.
14. A method as claimed in claim 12 or 13 wherein the porous tissue culture insert is a Millicell®-CM.
15. A method as claimed in claim 12 or 13 wherein at least one of the attachment factors is collagen.
16. A method as claimed in claim 12 or 13 wherein at least one of the attachment factors is type I collagen.
17. A method as claimed in claim 10 or 11 wherein the chondrocytes are isolated from articular cartilage of humans.
18. A method as claimed in claim 10 or 11 wherein the chondrocytes are isolated from bovine articular cartilage.
19. A method as claimed in claim 10 or 11, wherein the chondrocytes are isolated by sequential enzyme digestion of the articular cartilage tissue.
20. A method as claimed in claim 10 or 11 wherein the isolated chondrocytes are embryonic or mesenchymal cells.
21. A method as claimed in claim 12 or 13 wherein the attachment factors are selected from the group consisting of type I collagen, type II collagen, type IV collagen, a synthetic peptide of a segment of collagen, fibronectin, gelatin, laminin, polylysine, vitronectin. cytotactin, echinonectin, entactin, t'enascin, thro-Tibospondin, uvomorulin, biglycan, chondroitin sulfate, decorin, dermatan sulfate, heparin, and hyaluronic acid.
22. A method as claimed in claim 12 or 13, wherein the chondrocytes are cultured at a cell density of at least 0.1 cm2.
23. A method as claimed in claim 12 or 13, wherein the chondrocytes are cultured at a cell density of 1.0 to 7 3 106 cm2.
24. A method as claimed in claim 10 or 11, wherein the growth media is Ham's F12 medium.
25. A method as claimed in claim 10 or 11, wherein the chondrocytes are cultured for at least 14 days.
26. A method as claimed in claim 10 or 11 which further comprises implanting the tissue into a patient to replace or repair damaged or deficient cartilage.
27. A method as claimed in claim 10 or 11 which further comprises inserting the tissue into the site of a bone fracture in a patient to enhance healing of the bone fracture.
28. A method as claimed in claim 10 or 11 which further comprises subjecting the tissue to a pharmaceutical preparation which is suspected of being useful in the treatment of diseases of the joint and determining the effect of the pharamceutrical preparation on the tissue.
29. A method as claimed in claim 10 or 11 which further comprises subjecting the tissue to a substance which is suspected of effecting the growth of cartilage tissue and determining the effect of the substance on the tissue .
30. Cartilage tissue reconstituted in vitro by removing articular cartilage tissue from an animal; digesting said cartilage tissue to obtain isolated chondrocytes; forming a monolayer of chondrocytes on a substrate; culturing the chondrocytes in growth media to produce a tissue having a biochemical composition and three dimensional organization substantially the same as articular cartilage tissue.
PCT/CA1993/000111 1992-03-18 1993-03-18 Reconstituted cartilage tissue WO1993019168A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU38816/93A AU677953B2 (en) 1992-03-18 1993-03-18 Reconstituted cartilage tissue
JP51613193A JP3587305B2 (en) 1992-03-18 1993-03-18 Remodeled cartilage tissue
DE69328776T DE69328776T2 (en) 1992-03-18 1993-03-18 RECONSTRUCTED CARTILAGE TISSUE
CA002131904A CA2131904C (en) 1992-03-18 1993-03-18 Reconstituted cartilage tissue
EP93907686A EP0631619B1 (en) 1992-03-18 1993-03-18 Reconstituted cartilage tissue
AT93907686T ATE193550T1 (en) 1992-03-18 1993-03-18 RECONSTRUCTED CARTILAGE TISSUE
DK93907686T DK0631619T3 (en) 1992-03-18 1993-03-18 Reconstructed cartilage tissue
GR20000401884T GR3034190T3 (en) 1992-03-18 2000-08-14 Reconstituted cartilage tissue.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/835,831 1992-03-18
US07/835,831 US5326357A (en) 1992-03-18 1992-03-18 Reconstituted cartridge tissue

Publications (1)

Publication Number Publication Date
WO1993019168A1 true WO1993019168A1 (en) 1993-09-30

Family

ID=25270583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1993/000111 WO1993019168A1 (en) 1992-03-18 1993-03-18 Reconstituted cartilage tissue

Country Status (12)

Country Link
US (1) US5326357A (en)
EP (1) EP0631619B1 (en)
JP (1) JP3587305B2 (en)
AT (1) ATE193550T1 (en)
AU (1) AU677953B2 (en)
CA (1) CA2131904C (en)
DE (1) DE69328776T2 (en)
DK (1) DK0631619T3 (en)
ES (1) ES2146611T3 (en)
GR (1) GR3034190T3 (en)
PT (1) PT631619E (en)
WO (1) WO1993019168A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025961A1 (en) * 1995-02-22 1996-08-29 Ed Geistlich Söhne Ag Für Chemische Industrie Resorbable extracellular matrix for reconstruction of cartilage tissue
EP0735135A2 (en) * 1995-03-31 1996-10-02 DIZG Deutsches Institüt für Zell- und Gewebeersatz gGmbH Cell sheets and transport system for cell sheets
DE19540487A1 (en) * 1995-10-20 1997-04-24 Olaf Schultz Cell interaction system for induction of artificial 3-dimensional tissue
WO1997017430A1 (en) * 1995-11-06 1997-05-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
WO1997046665A1 (en) * 1996-06-04 1997-12-11 Sulzer Orthopedics Ltd. Method for making cartilage and implants
EP0812351A1 (en) * 1994-06-06 1997-12-17 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5786217A (en) * 1994-05-05 1998-07-28 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US6379367B1 (en) 1996-08-30 2002-04-30 Verigen Transplantation Service International (Vtsi) Ag Method instruments and kit for autologous transplantation
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6623963B1 (en) 1999-12-20 2003-09-23 Verigen Ag Cellular matrix
US6713085B2 (en) 2001-04-27 2004-03-30 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method and membrane for mucosa regeneration
EP1509118A2 (en) * 2002-05-13 2005-03-02 Articular Engineering, LLC Tissue engineered osteochondral implant
US6866668B2 (en) 1998-08-14 2005-03-15 Verigen Transplantation Service International (“VTSL”) AG Methods, instruments and materials for chondrocyte cell transplantation
US8354119B2 (en) 2001-11-20 2013-01-15 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen I and collagen II for reconstruction of cartilage
US8858981B2 (en) 1997-10-10 2014-10-14 Ed. Geistlich Soehne Fuer Chemistrie Industrie Bone healing material comprising matrix carrying bone-forming cells
US8911763B2 (en) 1997-10-10 2014-12-16 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material and method
US8945535B2 (en) 2005-09-20 2015-02-03 Zimmer Orthobiologics, Inc. Implant for the repair of a cartilage defect and method for manufacturing the implant
US9034315B2 (en) 1997-10-10 2015-05-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Cell-charged multi-layer collagen membrane

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
CA2175049A1 (en) * 1993-10-28 1995-05-04 Timothy Ringeisen Improved process and device for treating and healing a bone void
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5981825A (en) * 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
US5906827A (en) * 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US20020111695A1 (en) * 1995-11-06 2002-08-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
WO1997045147A1 (en) * 1996-05-28 1997-12-04 1218122 Ontario Inc. Resorbable implant biomaterial made of condensed calcium phosphate particles
CA2285382C (en) * 1997-04-04 2008-03-25 Barnes-Jewish Hospital Neocartilage and methods of use
EP0989855A4 (en) * 1997-05-13 2002-06-12 Osiris Therapeutics Inc Osteoarthritis cartilage regeneration using human mesenchymal stem cells
ES2320603T3 (en) 1997-07-30 2009-05-25 Emory University EXPRESSION SYSTEMS, VECTORS, DNA, OSEA MINERALIZATION PROTEINS NOVEDOSOS.
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US6378527B1 (en) * 1998-04-08 2002-04-30 Chondros, Inc. Cell-culture and polymer constructs
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
US6482401B1 (en) 1998-12-23 2002-11-19 Naturopathic Laboratories International, Inc. Composition for the relief of joint pain and myofascial pain and method of preparing same
US6197061B1 (en) * 1999-03-01 2001-03-06 Koichi Masuda In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage
WO2000073417A1 (en) 1999-05-27 2000-12-07 The Research Foundation Of State University Of New York In vitro cell culture device including cartilage and methods of using the same
US6179840B1 (en) 1999-07-23 2001-01-30 Ethicon, Inc. Graft fixation device and method
US20020095157A1 (en) 1999-07-23 2002-07-18 Bowman Steven M. Graft fixation device combination
JP2003512110A (en) * 1999-10-15 2003-04-02 マウント・シナイ・ホスピタル Synthetic substrate for tissue formation
CA2405345C (en) 2000-04-25 2012-09-18 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
WO2002000142A2 (en) * 2000-06-29 2002-01-03 Mount Sinai Hospital Intervertebral disc
IL137460A0 (en) * 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
AU2007203472B2 (en) * 2000-07-29 2011-07-14 Smith & Nephew Plc Tissue implant for cartilage repair
US9452238B2 (en) 2000-07-29 2016-09-27 Smith & Nephew LLP Tissue implant
JP2002233567A (en) * 2000-12-06 2002-08-20 Mitsuo Ochi Tissue equivalent for transplantation and its method of manufacture
US6599323B2 (en) * 2000-12-21 2003-07-29 Ethicon, Inc. Reinforced tissue implants and methods of manufacture and use
CA2365376C (en) * 2000-12-21 2006-03-28 Ethicon, Inc. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US6852330B2 (en) * 2000-12-21 2005-02-08 Depuy Mitek, Inc. Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US20020127265A1 (en) * 2000-12-21 2002-09-12 Bowman Steven M. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
CA2438047A1 (en) * 2001-02-14 2002-08-22 Hildegard M. Kramer Biocompatible fleece for hemostasis and tissue engineering
US8227240B2 (en) * 2001-08-14 2012-07-24 The Washington University Systems for screening pharmaceutical chemicals
AU2002356043A1 (en) * 2001-08-14 2003-03-03 Washington University In St. Louis Systems and methods for screening pharmaceutical chemicals
US7476257B2 (en) * 2001-09-15 2009-01-13 Rush University Medical Center Methods to engineer stratified cartilage tissue
EP1437147B1 (en) * 2001-09-25 2012-06-27 National Institute for Environmental Studies Method of preparing basement membrane
US20030165473A1 (en) * 2001-11-09 2003-09-04 Rush-Presbyterian-St. Luke's Medical Center Engineered intervertebral disc tissue
US20030138873A1 (en) * 2002-01-22 2003-07-24 Koichi Masuda Tissue engineered cartilage for drug discovery
JP2005516972A (en) * 2002-01-22 2005-06-09 ファイザー・インク 3- (imidazolyl) -2-aminopropionic acid used as TAFI-A inhibitor for the treatment of thrombotic diseases
US20050069572A1 (en) * 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
US7824701B2 (en) * 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US20040078090A1 (en) * 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffolds with tissue fragments
CN100412188C (en) * 2003-02-21 2008-08-20 Uab研究基金会 Biologically active native biomatrix composition
US8197837B2 (en) 2003-03-07 2012-06-12 Depuy Mitek, Inc. Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof
DE10312144B4 (en) * 2003-03-13 2006-12-14 Technische Universität Dresden Carrier material for tissue and cell culture and the production of implant materials
JP4676679B2 (en) * 2003-04-02 2011-04-27 帝人株式会社 Artificial cartilage
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US7488348B2 (en) 2003-05-16 2009-02-10 Musculoskeletal Transplant Foundation Cartilage allograft plug
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US10583220B2 (en) 2003-08-11 2020-03-10 DePuy Synthes Products, Inc. Method and apparatus for resurfacing an articular surface
GB0320691D0 (en) * 2003-09-04 2003-10-01 Smith & Nephew Use of joint lining cells for articular cartilage repair
US20050074744A1 (en) * 2003-10-02 2005-04-07 Dibenedetto Peter Assays for evaluating anti-osteoarthritic activity
DE10349722A1 (en) 2003-10-23 2005-06-16 Beschorner, Katharina, Dr. Composition for arthritis / arthritis treatment, in particular of joints
US7316822B2 (en) 2003-11-26 2008-01-08 Ethicon, Inc. Conformable tissue repair implant capable of injection delivery
US7901461B2 (en) 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
WO2005058207A1 (en) 2003-12-11 2005-06-30 Isto Technologies, Inc. Particulate cartilage system
US11395865B2 (en) * 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US20060275273A1 (en) * 2004-02-20 2006-12-07 Seyedin Mitchell S Intervertebral Disc Repair, Methods and Devices Therefor
WO2005081870A2 (en) * 2004-02-20 2005-09-09 Isto Technologies, Inc. Intervertebral disc repair, methods and devices therefor
US8221780B2 (en) 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8137686B2 (en) 2004-04-20 2012-03-20 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8657881B2 (en) * 2004-04-20 2014-02-25 Depuy Mitek, Llc Meniscal repair scaffold
US7273756B2 (en) * 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8017394B2 (en) * 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
JP4044579B2 (en) * 2005-08-02 2008-02-06 株式会社Pgリサーチ Artificial cartilage tissue
EP1916964A4 (en) 2005-08-26 2015-11-04 Zimmer Inc Implants and methods for repair, replacement and treatment of joint disease
WO2007032404A1 (en) * 2005-09-16 2007-03-22 St. Marianna University, School Of Medicine Biomaterial for regenerative medicine
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
US7544141B2 (en) * 2006-07-18 2009-06-09 Gm Global Technology Operations, Inc. Transmission device with selectable motor connections
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
AU2008240191B2 (en) 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
WO2009111069A1 (en) 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
CN102099458A (en) 2008-06-05 2011-06-15 威斯康星医学院公司 Three dimensional tissues for high-throughput assays
SG11201500189PA (en) 2012-07-11 2015-03-30 Osiris Therapeutics Inc Porated cartilage products
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US10195044B2 (en) 2013-07-12 2019-02-05 Sinai Health System Intervertebral disc implant
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175286A2 (en) * 1984-09-14 1986-03-26 MCW Research Foundation, Inc. In vitro cell culture system and method
WO1990012603A1 (en) * 1989-04-17 1990-11-01 Vacanti Joseph P Neomorphogenesis of cartilage in vivo from cell culture
EP0396138A2 (en) * 1989-05-04 1990-11-07 Millipore Corporation Method for growing cellular tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703575A (en) * 1970-12-23 1972-11-21 Heinrich Thiele Reconstructed cartilaginous tissue and method of implanting it into the human or animal body
US4356261A (en) * 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5037656A (en) * 1986-12-04 1991-08-06 Millipore Corporation Porous membrane having hydrophilic and cell growth promotions surface and process
US4846835A (en) * 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5053050A (en) * 1988-04-29 1991-10-01 Samuel Itay Compositions for repair of cartilage and bone
US4904259A (en) * 1988-04-29 1990-02-27 Samuel Itay Compositions and methods for repair of cartilage and bone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175286A2 (en) * 1984-09-14 1986-03-26 MCW Research Foundation, Inc. In vitro cell culture system and method
WO1990012603A1 (en) * 1989-04-17 1990-11-01 Vacanti Joseph P Neomorphogenesis of cartilage in vivo from cell culture
EP0396138A2 (en) * 1989-05-04 1990-11-07 Millipore Corporation Method for growing cellular tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH vol. 186, June 1984, PHILADELPHIA, PA, US pages 231 - 239 T. KIMURA ET AL. 'CHONDROCYTES EMBEDDED IN COLLAGEN GELS MAINTAIN CARTILAGE PHENOTYPE DURING LONG-TERM CULTURES.' *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786217A (en) * 1994-05-05 1998-07-28 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
EP0812351A1 (en) * 1994-06-06 1997-12-17 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
EP0812351A4 (en) * 1994-06-06 1998-07-08 Advanced Tissue Sciences Inc Three-dimensional cartilage cultures
US6326029B1 (en) 1995-02-22 2001-12-04 Ed Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix for reconstruction of cartilage tissue
WO1996025961A1 (en) * 1995-02-22 1996-08-29 Ed Geistlich Söhne Ag Für Chemische Industrie Resorbable extracellular matrix for reconstruction of cartilage tissue
US6676969B2 (en) 1995-02-22 2004-01-13 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix for reconstruction of cartilage tissue
US7208177B2 (en) 1995-02-22 2007-04-24 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix for reconstruction of cartilage
EP0735135A2 (en) * 1995-03-31 1996-10-02 DIZG Deutsches Institüt für Zell- und Gewebeersatz gGmbH Cell sheets and transport system for cell sheets
EP0735135A3 (en) * 1995-03-31 1997-12-29 DIZG Deutsches Institüt für Zell- und Gewebeersatz gGmbH Cell sheets and transport system for cell sheets
DE19540487A1 (en) * 1995-10-20 1997-04-24 Olaf Schultz Cell interaction system for induction of artificial 3-dimensional tissue
WO1997017430A1 (en) * 1995-11-06 1997-05-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
US6464729B1 (en) 1995-11-06 2002-10-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
US6242247B1 (en) 1996-06-04 2001-06-05 Sulzer Orthopedics Ltd. Method for making cartilage and implants
US6387693B2 (en) 1996-06-04 2002-05-14 Sulzer Orthopedics Ltd. Method for producing cartilage tissue and implants for repairing enchondral and osteochondral defects as well as arrangement for carrying out the method
WO1997046665A1 (en) * 1996-06-04 1997-12-11 Sulzer Orthopedics Ltd. Method for making cartilage and implants
US6592599B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6379367B1 (en) 1996-08-30 2002-04-30 Verigen Transplantation Service International (Vtsi) Ag Method instruments and kit for autologous transplantation
US6592598B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6599300B2 (en) 1996-08-30 2003-07-29 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6599301B2 (en) 1996-08-30 2003-07-29 Verrgen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US7048750B2 (en) 1996-08-30 2006-05-23 Verigen Ag Method, instruments, and kits for autologous transplantation
US7137989B2 (en) 1996-08-30 2006-11-21 Verigen Ag Method, instruments, and kit for autologous transplantation
US9034315B2 (en) 1997-10-10 2015-05-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Cell-charged multi-layer collagen membrane
US8911763B2 (en) 1997-10-10 2014-12-16 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material and method
US8858981B2 (en) 1997-10-10 2014-10-14 Ed. Geistlich Soehne Fuer Chemistrie Industrie Bone healing material comprising matrix carrying bone-forming cells
US6866668B2 (en) 1998-08-14 2005-03-15 Verigen Transplantation Service International (“VTSL”) AG Methods, instruments and materials for chondrocyte cell transplantation
US6623963B1 (en) 1999-12-20 2003-09-23 Verigen Ag Cellular matrix
US6713085B2 (en) 2001-04-27 2004-03-30 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method and membrane for mucosa regeneration
AU2002334852B2 (en) * 2001-10-03 2007-08-09 Genzyme Corporation Method, instruments, and kit for autologous transplantation
WO2003028545A3 (en) * 2001-10-03 2003-06-19 Verigen Ag Method, instruments, and kit for autologous transplantation
US8354119B2 (en) 2001-11-20 2013-01-15 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen I and collagen II for reconstruction of cartilage
EP1509118A4 (en) * 2002-05-13 2010-11-10 Articular Engineering Llc Tissue engineered osteochondral implant
EP1509118A2 (en) * 2002-05-13 2005-03-02 Articular Engineering, LLC Tissue engineered osteochondral implant
US8945535B2 (en) 2005-09-20 2015-02-03 Zimmer Orthobiologics, Inc. Implant for the repair of a cartilage defect and method for manufacturing the implant

Also Published As

Publication number Publication date
JP3587305B2 (en) 2004-11-10
CA2131904A1 (en) 1993-09-30
EP0631619B1 (en) 2000-05-31
PT631619E (en) 2000-09-29
AU3881693A (en) 1993-10-21
DE69328776D1 (en) 2000-07-06
EP0631619A1 (en) 1995-01-04
ATE193550T1 (en) 2000-06-15
ES2146611T3 (en) 2000-08-16
DK0631619T3 (en) 2000-10-09
GR3034190T3 (en) 2000-11-30
DE69328776T2 (en) 2000-11-09
US5326357A (en) 1994-07-05
CA2131904C (en) 2007-10-16
JPH07505620A (en) 1995-06-22
AU677953B2 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
EP0631619B1 (en) Reconstituted cartilage tissue
US6485723B1 (en) Enhanced submucosal tissue graft constructs
US6179872B1 (en) Biopolymer matt for use in tissue repair and reconstruction
EP0946127B1 (en) Biopolymer foams for use in tissue repair and reconstruction
KR100365573B1 (en) Transplantation tissue and its manufacturing method
Pei et al. Bioreactors mediate the effectiveness of tissue engineering scaffolds
Tona et al. Extracellular matrix in regenerating rat sciatic nerve: a comparative study on the localization of laminin, hyaluronic acid, and chondroitin sulfate proteoglycans, including versican.
WO1999047186A1 (en) Chitosan-based composite materials containing glycosaminoglycan for cartilage repair
KR20040074054A (en) Stratified cartilage tissue and methods to engineer same
AU7100398A (en) Neocartilage and methods of use
Götz et al. Localisation of extracellular matrix components in the embryonic human notochord and axial mesenchyme.
CA2323797A1 (en) Biopolymer matt for use in tissue repair and reconstruction
AU766719B2 (en) Enhanced submucosal tissue graft constructs
KR20030010636A (en) Collagen-based supports for tissue engineering and manufacture of biomaterials
KR100715505B1 (en) Method for preparing a cell-derived extracellular matrix scaffold
KR20090013425A (en) Method for differenciating mesenchymal stem cell and culturing chondrocytes using alginate coated fibrin/ha composite scaffold
Abrahamsson et al. Restoration of the Injured Flexor Tendon Surface: A Possible Role for Endotenon Cells: A morphological study of the rabbit tendon in vivo
KR100684778B1 (en) Method for Inducing Chondrogenesis From Ultrasound Pretreated Mesenchymal Stem Cells
Hemmen Cellular and molecular aspects of articular cartilage resurfacing
Thomas The Effects of Extracellular Matrix Components on Chondrocyte Gene Expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993907686

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2131904

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1994 302885

Country of ref document: US

Date of ref document: 19941205

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1993907686

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993907686

Country of ref document: EP